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Background: Domestic violence and abuse (DVA), defined as threatening behavior or abuse by adults who are
intimate partners or family members, is a key public health and clinical priority. The prevalence of DVA in the
United Kingdom and worldwide is high, and its impact on physical and mental health is detrimental and persistent.
There is currently little support within healthcare settings for women experiencing DVA. Psychological problems in
particular may be difficult to manage outside specialist services, as conventional forms of therapy such as
counseling that do not address the violence may be ineffective or even harmful. The aim of this study is to assess
the overall effectiveness and cost-effectiveness of a novel psychological intervention tailored specifically for
survivors of DVA and delivered by domestic violence advocates based in third-sector organizations.
Methods and study design: This study is an open, pragmatic, parallel group, individually randomized controlled
trial. Women ages 16 years and older experiencing domestic violence are being enrolled and randomly allocated to
receive usual DVA agency advocacy support (control) or usual DVA agency support plus psychological intervention
(intervention). Those in the intervention group will receive eight specialist psychological advocacy (SPA) sessions
weekly or fortnightly, with two follow-up sessions, 1 month and then 3 months later. This will be in addition to any
advocacy support sessions each woman receives. Women in the control group will receive usual DVA agency
support but no additional SPA sessions. The aim is to recruit 250 women to reach the target sample size. The
primary outcomes are psychological well-being and depression severity at 1 yr from baseline, as measured by the
Clinical Outcomes in Routine Evaluation–Outcome Measure (CORE-OM) and the Patient Health Questionnaire
(PHQ-9), respectively. Secondary outcome measures include anxiety, posttraumatic stress, severity and frequency of
abuse, quality of life and cost-effectiveness of the intervention. Data from a subsample of women in both groups
will contribute to a nested qualitative study with repeat interviews during the year of follow-up.
Discussion: This study will contribute to the evidence base for management of the psychological needs of women
experiencing DVA. The findings will have important implications for healthcare commissioners and providers, as
well as third sector specialist DVA agencies providing services to this client group.
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Domestic violence and abuse (DVA) is threatening behav-
ior, violence or abuse (psychological, physical, sexual, or
financial), characterized by coercive control, perpetrated
by adults who are or have been intimate partners or family
members. DVA is common; the 2009/10 British Crime
Survey [1] reported that 29% of women had experienced
abuse from a partner, ex-partner or family member at
some time in their lives. The World Health Organization
multicountry study (15 sites in 12 countries) [2] reported
estimated lifetime prevalence rates of physical or sexual
partner violence, or both, that ranged from 15% to 71%
worldwide. Women who experience DVA often have poor
physical and mental health, thus making DVA a key public
health and clinical priority [3]. The cost of DVA to the UK
economy, including costs to the government and em-
ployers as well as in terms of human suffering, has been
estimated to be £16 billion [4].
Over and above damage to physical health [5,6] and
reproductive health [7], DVA has long-term detrimental
effects on mental health. It is the leading contributor to
the global burden of mental health problems among
women of reproductive age [8]. The impact of DVA has
psychological parallels with the trauma of being taken
hostage and subjected to torture [9,10]. Golding’s land-
mark meta-analysis [11] of 41 studies, mostly North
American, measuring the relationship between domestic
violence and mental illness, reported increased risks for a
range of conditions including depression, posttraumatic
stress disorder (PTSD), substance use and suicidality. Our
UK-based study of women with a lifetime experience of
DVA attending general practices in East London [12]
found odds ratios greater than 3 for depression, anxiety
and PTSD and greater than 2 for suicide attempts, use of
illegal drugs and alcohol abuse.
There is limited evidence for the effectiveness of psy-
chological interventions for victims of DVA. Access to
psychological support within the National Health Service
(NHS) in the United Kingdom is often difficult [13], and
standard psychological interventions such as counseling
and cognitive-behavior therapy (CBT) that are not
adapted to the specific needs of this vulnerable group
have often failed to meet their needs. Service users have
found it unhelpful when interventions do not recognize
trauma, make the abuser invisible by focusing exclusively
on the mental health of the victim (implicitly or explicitly),
blame the victim for the abuse or her reaction, offer medi-
cation rather than counseling and assign a psychiatric
diagnosis that negatively affects care or contact proceed-
ings. In contrast, women identify interventions as helpful
when they are encouraged to name domestic violence, are
directly asked about their experiences of abuse, are helped
with safety planning or parenting and are offered support
to recover from their experiences [14]. Psychologicalinterventions may not directly address the violence,
and couples or family therapy in which the victim
and perpetrator are treated conjointly are potentially
dangerous [15,16]. A systematic review [17] found very
few studies that examined the effectiveness of different in-
terventions in reducing psychological distress or improv-
ing mental health outcomes of women who experience
DVA. Modest improvements have been shown in two
randomized controlled trials [18,19] using an individual
cognitive therapy–based intervention for the treatment of
posttraumatic stress in DVA survivors who are no longer
in abusive relationships. However, the results of these
studies cannot be extrapolated to women with other
mental health conditions or to women still in abusive
relationships.
A novel psychological intervention specifically tailored
for women experiencing DVA, Psychological Advocacy
Towards Healing (PATH), has been developed by
Agnew-Davies and colleagues [20]. The PATH model
draws from different concepts and technical strategies
within CBT, experiential, dynamic, psychoeducational
and feminist theories. This model has been piloted with
a sample of 106 women in refuge settings [20,21] and
has been shown to lead to a reduction in women’s psy-
chological distress as assessed by the clinical outcomes
measured using a routine evaluation outcome measure,
the Clinical Outcomes in Routine Evaluation–Outcome
Measure (CORE-OM). In that pilot study, using a
before-and-after design, the researchers found there was
a reduction in mean total CORE score from 1.72 to 1.34
(conventional clinical cut-off of 1.29).
Women with a recent history of DVA have mental
health needs that are not being met in primary care or
mental health services. The United Kingdom has a net-
work of DVA advocacy and support services, most of
which are affiliated with the Women’s Aid Federation
(http://www.womensaid.org.uk/). Advocates engage with
individual clients who are being or have been abused,
aiming to empower them and linking them with com-
munity services. The core activities of advocacy are
provision of legal, housing and financial advice; facilitat-
ing access to and use of community resources such as
refuges or shelters, emergency housing; provision of
safety planning advice; and provision of ongoing support.
The duration and intensity of advocacy varies within and
between agencies. Generally, advocates do not have a
background or training in psychological therapies and
do not provide counseling or other therapies. Although
advocacy may reduce recurrence of violence, its effect
on mental health and quality of life is uncertain [22].
In this study, we are training DVA advocates in the
PATH model to enable them to deliver a specialist
trauma-focused intervention to the women accessing
their services. This trial will evaluate the model’s overall
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ive of the PATH trial is to determine the extent to which
women experiencing DVA who are referred or have self-
referred to a specialist DVA agency will have improved
quality of life and mental health outcomes if they receive
a psychological intervention alongside DVA agency sup-
port compared with DVA agency support alone. Second-
ary objectives are to compare the cost-effectiveness of
the two interventions and to investigate differences in
the severity and frequency of abuse. A nested qualita-
tive study to explore client perceptions of the interven-
tion to inform interpretation of the results will also be
conducted.
Methods
Design
This is an open, pragmatic, two-parallel-group, individu-
ally randomized controlled trial. Women seeking help
from specialist DVA agencies are randomized at a 1:1 ra-
tio to usual DVA agency support or usual DVA agency
support plus additional psychological support from a
specially trained advocate or support worker. Two hun-
dred fifty women are being recruited into the study at
two DVA agencies, both in the United Kingdom. Partici-
pants are enrolled in the study for 1 yr, during which
time they will all have access to usual support from the
DVA agency. The primary outcome is assessed at 1 yr
from randomization.
Participants
Participants are eligible for inclusion if they are experi-
encing domestic violence or abuse which has led them
to seek support from one of the recruiting sites and are
age 16 years or older. Women are excluded if they (1)
have a psychotic illness, (2) have a severe drug or alcohol
problem, (3) are unable to read English or (4) are cur-
rently attending counseling, CBT or other psychological
treatments in either primary care or specialist psychiatric
services.
Recruitment is taking place at two sites: Bristol Next Link
(http://www.nextlinkhousing.co.uk/) and Cardiff Women’s
Aid (http://www.cardiffwomensaid.org.uk/). All women
who present to the DVA agencies are assessed for eligibility
and invited to consider participation as part of the service’s
routine intake procedures. Women who are potentially
interested in participating are then referred to a female
researcher who meets with them face-to-face at a safe and
convenient location.
All women referred to the study are provided with a
written patient information sheet and have the oppor-
tunity to discuss the study with the researcher. Informed
consent is obtained from each participant in writing.
After the woman consents to participate in the study, the
researcher works with her to develop an individualizedschedule which includes safety information and the details
of friends, family or associates (locators) who will be able
to help the researcher to contact the woman if contact is
lost. The participant is then asked to complete a baseline
questionnaire. On completion, the researcher randomizes
the participant by using a remote, independent, automated
telephone randomization service provided by the Bristol
Randomized Trials Collaboration (http://www.bristol.ac.
uk/social-community-medicine/centres/brtc/). Randomiza
tion is stratified by whether women receive support from
the safe house team or from the resettlement team at Next
Link and the refuge team or tenant support team at
Cardiff Women’s Aid. The randomization program applies
stratification with random blocking. Within each stratum,
participants are assigned to the treatment group (T) or
control group (C) in randomly chosen blocks of two, four
or six. Within each block, the order of assignment is also
random, so that in a group of four, for example, the per-
mutation TCTC would be equally as likely as TTCC. For
each completed block, the allocation ratio is 1:1, so that
the number of Ts and Cs will be equal. Allocation is
concealed from the researcher until the moment of
randomization.
Over the course of the study, women are requested to
complete three further questionnaires, at 4, 8 and 12 mo
after randomization. Questionnaires are either hand-
delivered or sent to the women, depending on the stated
preference. Women receive a £10 shopping token after
completing the baseline, 4- and 8-month questionnaires
and £20 for completion of the 12-months questionnaire.
To retain women in the study, researchers make mid-
point contacts with women between follow-up points.
When researchers are unable to contact a woman on
four consecutive occasions, they begin to work through
the locator contacts given by the women at the point of
recruitment into the study. When a woman cannot be lo-
cated, researchers continue to use the woman’s last known
details. Women are prompted to return questionnaires at
2, 4 and 6 wk after the questionnaires are sent or deliv-
ered. Failure to return a questionnaire by week 7 prompts
the researcher to begin working through the women’s lo-
cator contacts. Researchers continue to prompt women
(or their locators) for the return of questionnaire until
week 12 after posting. The researcher will call the woman
by telephone and, if no answer is received, leave a voice
message (unless it has been explicitly stated that it is
not safe to do so). After two failed telephone contact
attempts, the researcher will send a text message to the
woman’s last known mobile telephone number. If there is
still no response, the researcher sends a handwritten card
to the woman’s last known address. Failure to return a
questionnaire by week 12 (after it was sent or deliv-
ered) results in the questionnaire’s being noted as
missing. Researchers will continue to issue the next
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tionnaire was not returned.
Intervention
Women randomized to receive psychological support in
addition to usual DVA agency support will be assigned a
specialist psychological advocate (SPA) who has gone
through a 25-day manualized training program from a
clinical psychologist with expertise in DVA (RAD). The
training addresses the psychological impacts of DVA on
women and develops therapeutic skills specifically tai-
lored for this client group. SPAs are trained to work with
women with common presenting problems within a
single-session model [23] using a session structure (find-
ing a focus for work, obtaining a commitment to work,
working on a specific topic, evaluation of progress and
homework) based on the work of Daldrup and colleagues
[24]. Topics covered include posttraumatic stress, depres-
sion, anxiety, low self-esteem, unresolved anger and
managing loss. SPAs are also provided with handouts
and self-help resources that can be used with their cli-
ents. Supervision of the SPAs is provided by the clinical
psychologist, who listens to a sample of recorded
SPA sessions and provides feedback through regular
telephone or email contact and periodic face-to-face
meetings.
Once assigned a SPA, the participant will attend eight
SPA sessions, meeting either weekly or fortnightly dur-
ing the course of 2 to 3 months, with a further two
booster sessions, 1 and then 3 months later. During SPA
sessions, the advocates will provide time-limited inter-
ventions using a variety of primarily CBT psychological
techniques, focusing within any one session on a specific
presenting problem, such as hyperarousal, sleeping diffi-
culties or parenting problems. The advocate will aim to
empower the client to apply therapeutic strategies (such
as relaxation, challenging thoughts or goal-setting) to
promote recovery from each problem. Each series of
eight sessions varies according to the client’s presenting
problems, but typically includes discussions about the
impact of domestic abuse on mental health and common
reactions, typically including posttraumatic stress and
low self-esteem. The client selects a specific topic for
each session, and the SPA will use written resources to
guide identification of signs (symptoms), the association
with experiences of abuse and strategies to overcome
them within that session, and through homework tasks
to be completed between sessions. Each of the eight ses-
sions can have different content for any therapeutic
dyad, although SPAs will focus on building the alliance
and safety in the first session and address endings and
closure in the eighth session. The follow-up sessions 1
and 3 months after the eighth session are focused on
consolidating gains.In addition, the woman will receive the usual support
or advocacy provided by the DVA agencies. This support
can involve assistance with a variety of health and social
issues, including housing problems, budgeting and debt,
and legal proceedings. There is evidence that advocacy
on its own can reduce physical abuse and possibly
improve quality-of-life outcomes for women who have
experienced DVA. Importantly, usual advocacy also pro-
vides a space for women to share their experiences and
talk about their feelings in a safe and nonjudgmental
environment.
Control participants will have access to the usual DVA
agency support and advocacy as described above. They
will not receive SPA sessions, and their support worker
advocate will not have received specialist training in psy-
chological methods. The length of time a woman can be
engaged with a DVA agency varies, depending on their
needs and the service’s policies. Support can range from
a one-off session with onward referral to regular meet-
ings over a period of months.
We are not using an attention control group, as this
trial is designed (and funded) explicitly as a pragmatic
(effectiveness), not explanatory (efficacy), trial, building
on previous trial evidence for the effectiveness of psy-
chological and advocacy interventions. Therefore, it is
legitimate to have a treatment-as-usual rather than an
attention control group. We will collect data on contact
time between advocates and participants in both arms
and will use that in our interpretation of the findings.
Primary outcomes
This study has two primary outcomes, both collected
at 1 yr after randomization. The first is the Clinical
Outcomes in Routine Evaluation–Outcome Measure
(CORE-OM) score [25]. CORE-OM is a standardized,
validated global measure of psychological distress
based on a self-completed 34-item questionnaire, with
established sensitivity to change, good test-retest reli-
ability and UK normative data. It was designed to assess
efficacy and effectiveness across multiple disciplines offer-
ing psychological therapies [26]. The second is the Patient
Health Questionnaire (PHQ-9) score [27], which is a
widely used, self-completed measure of depression [27]
with extensive validation in diverse populations with
sensitivity to change, leading to its adoption across a wide
range of trials internationally.
Secondary outcomes
Some further validated mental health measures are being
used: the Generalized Anxiety Disorder 7 scale (GAD-7)
[28], the Posttraumatic Stress Disorder CheckList devel-
oped by Weathers et al. [29], the Composite Abuse Scale
to measure type and severity of abuse [30], the Short
Form-12 Health Survey to measure quality of life [31]
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[32]. All secondary outcomes will be measured at 4, 8
and 12 mo by questionnaire. Data derived from the
PHQ-9 and CORE-OM questionnaires at 4 and 8 months
will also be treated as secondary outcomes and will be
used for imputation in the absence of 12-month outcome.
For the economic evaluation, data will be collected on
the women’s use of health, social and criminal justice
services. We will also collect data on expenses incurred
by the women for attending appointments, such as travel
and child-care costs. Resource use by children of partici-
pants will also be measured, such as appointments with
youth offender teams and school attendance, as many
of the effects of DVA on children and young people
manifest as psychological, social, educational and/or
behavioral difficulties [33-35]. These data will be collected
by questionnaire at the same time points as the above out-
come measures.
Other data
Other variables collected in the participant question-
naires are age, number of children at home, ethnicity,
income, occupation and relationship to perpetrator. The
following process data are recorded by the domestic vio-
lence advocates working with the participant: number of
DVA agency sessions the participant attends; the main
focus of each session; and advocates’ contact time with
participants, number of women entering the DVA ser-
vice who do not meet the eligibility criteria or who are
not interested in participating. We will also collect data
on adverse events self-reported by the participant (ver-
bally and/or by questionnaire) or elicited by the DVA
advocate following contact with her.
Sample size
Using pilot data, the sample size is based on being able
to detect a difference of 0.5 in the CORE-OM score, a
“reliable change index” [25]. This will be the difference
in psychological distress between intervention and con-
trol groups as measured by the CORE-OM question-
naire 12 months after each patient is randomly assigned.
A sample size of 200 participants in total gives a power
of 96% to detect a difference of 0.5 on the CORE-OM,
corresponding to an effect size of 0.5 and 81% power to
detect an effect size of 0.4. Assuming an attrition of
20%, we will need to recruit 250 women.
An effect size of 0.4 to 0.5 is consistent with effect
sizes detected in studies of psychological interventions
using the CORE-OM as an outcome measure [36] and is
similar to that of CBT interventions on the PHQ-9 and
other depression outcome measures [37]. An effect size
in the 0.4 to 0.5 range is also comparable to the outcome
of trials of psychological interventions for women who
have experienced domestic violence (see Appendix 7.5 inour systematic review of interventions [38]). For ex-
ample, Kubany and colleagues’ two trials of CBT for
women diagnosed with PTSD following intimate partner
violence reported effect sizes of 0.9 [19] and 0.33 [18],
respectively, for PTSD and 0.4 and 0.25, respectively, for
depression outcomes. Labrador et al. [39] reported effect
sizes of 1.23 and 1.77 for PTSD and depression out-
comes, respectively, and Reed and Enright [40] reported
effect sizes of 2.33 and 1.55 for PTSD and depression,
respectively.
Nested qualitative study
A sample of approximately 30 women across both trial
groups from both recruiting sites will be invited to take
part in a series of three interviews spaced across their
year of participation. The aim of these interviews will be
to explore women’s assessment of their mental well-
being and quality of life in their own words, as well as
the overall acceptability and perceived effectiveness of
the services they received. Topic guides include ques-
tions that explore which of the therapeutic strategies
(such as exercises to resolve anger, challenging negative
thoughts or goal setting) were most useful to the women
and why. Interviews are face-to-face and will last up to
one hour. With participants’ consent, interviews will be
recorded and transcribed verbatim. Purposive sampling
based on data collected in the baseline questionnaires
will ensure a diverse group of informants in terms of
age, currency of abuse, and mental health status.
Statistical analysis
Trial outcomes will be analyzed and reported in accord-
ance with Consolidated Standards of Reporting Trials
(CONSORT) guidelines. Baseline demographic data such
as gender, age, duration of abuse and relationship to per-
petrator will be summarized and descriptive summary
statistics will be provided to check for imbalances
between the two trial groups. For variables with continu-
ous measures, we will report the mean and standard devi-
ation, and for categorical data, we will report frequencies
and percentages.
Because the allocation will be stratified by site (Bristol
vs Cardiff ) and type of setting where the treatment is
administered (safe house vs within community), the
comparative analyses will adjust for these two factors.
These will involve normal and logistic regression ana-
lyses for continuous and binary outcomes, respectively,
and also, where appropriate, will adjust for the baseline
scores of the outcome variables. The primary comparative
analysis will compare continuous CORE-OM scores be-
tween the two groups as randomized using an intention-
to-treat regression model. Secondary analysis will adjust
for any factors exhibiting substantial baseline imbalance;
further secondary analyses will include prespecified
Brierley et al. Trials 2013, 14:221 Page 6 of 9
http://www.trialsjournal.com/content/14/1/221subgroup analyses according to the two stratification vari-
ables and age, which will be investigated by introducing
the relevant interaction with treatment group into the re-
gression model [41]. It is possible that the treatment effect
will differ across both sites and settings because of demo-
graphic differences between Cardiff and Bristol and differ-
ences in community and safe house or refuge settings. It is
also likely that treatment impact will differ between age
groups, partly in connection with baseline exposure to vio-
lence, which tends to be higher in the younger strata of the
population [1,42]. The subgroup analysis by age will use
the median as a threshold to separate younger from older
women in the sample as well as use age as a continuous
variable in two separate specifications. Because rapport with
the therapist (in this case, the specialist psychological advo-
cate) is a key component of therapy effectiveness [43-45],
we will also account for potential differences in impact at
the therapist level in generalized mixed models. To assess
the stability of any treatment effect, we will fit a mixed
model for CORE-OM or PHQ-9 scores at 4, 8 and 12
months, adjusted for baseline CORE-OM or PHQ-9, using
number of treatment sessions as a fixed categorical effect.
The impact of, and reasons for, missing data will be in-
vestigated in sensitivity analyses based on multiple im-
putation by chained equation models (mice) [46-49].
The imputation model will contain all the variables pre-
dictive of missingness and of the outcome, as well as
those in the hypothesized model [48]. The number of
imputations will be determined on the basis of the per-
centage of data that will be missing, as well as on the
precision of the estimate [48]. A random coefficient
mixed effects model will also be considered in compar-
ing groups in terms of CORE-OM and PHQ-9 scores. A
mixed (fixed and random) effects model will allow us to
account for the distribution of errors, compared with
fixed effects models [50] and to deal with missing data
were these not to be missing at random [51].
We will calculate complier-average causal effect (CACE)
using instrumental variables techniques to establish a
stronger causal link between assignment to treatment and
impact in the absence of full adherence to the treatment
[46,52,53]. In particular, it is possible that different individ-
uals will complete treatment at a different pace than that
envisaged by the trial team, and these models will take this
heterogeneity into account. To calculate CACE estimates,
adherence will be represented primarily by the number of
treatment sessions attended. Where a binary version is re-
quired, we will in the first instance consider completion of
at least four sessions at 12 months from randomization as
reflecting adequate adherence.
Economic analysis
Although there is literature on the economic impact of
DVA, to date there has been little economic analysis ofinterventions aimed at improving outcomes for domestic
violence survivors [54]. The aim of the economic evalu-
ation is to compare the extra cost of providing the
PATH intervention with the extra benefits gained to
allow judgment about its cost-effectiveness. This process
involves detailed individual-level costing of caring for
women who are victims of DVA. The cost of caring for
women offered the PATH intervention (that is, sessions
with the SPAs) will be compared with the cost of domes-
tic violence advocacy alone. The analysis will consider
costs associated with the delivery of care from the per-
spectives of the NHS and personal social services (PSSs),
the public sector and society in general. Resource use
will be measured from the point of randomization until
final follow-up 12 mo later. Data will be collected by
means of a questionnaire at 4, 8 and 12 mo, and the ana-
lysis will include all resources used by the women unless
clearly unrelated to domestic violence, including relevant
resources used by or on behalf of children younger than
age 17 years in their care.
We will report the direct costs of the intervention. Be-
cause the training curriculum was developed prior to the
intervention [20,21], start-up costs pertain only to train-
ing of the SPAs. Delivering the intervention requires
SPA time, clinical supervision and management by the
host domestic violence agency. We will quantify time
with the use of timesheets and the original budgets. This
time will be valued at advocates’ and trainers’ salaries
and management costs paid to the host agencies.
Use of NHS and PSS resources will be captured
through the questionnaire. These will include primary
and community health services, prescribed medication
and use of hospital services. Unit costs for the valuation
of these resources will be derived using the method de-
scribed by Curtis [55], Department of Health reference
costs and the British National Formulary. Community
and social care services (such as family therapists and
social workers) provide day-to-day support to DVA vic-
tims and their children to help them cope with the
trauma and aftermath of domestic abuse. We will meas-
ure residence in refuges or safe houses by participants
during the 1-yr follow-up period, estimating costs from
information given by participating agencies and other
refuge providers. Use of legal services as a consequence
of DVA will be measured using our questionnaire, and
we will derive relevant unit costs from current aggregate
estimates [56]. Finally, in line with the societal perspec-
tive in this analysis, we will also quantify personal and
social costs caused by the exposure to DVA. These will
include personal outlay for travel, child care and change
in housing circumstances, as well as the use of voluntary
sector services and time off from work.
We will present results using a cost consequences
framework comparing cost from each perspective with
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EQ-5D data from the study questionnaires to construct
quality-adjusted life years (QALYs) and present an incre-
mental cost-effectiveness ratio. This will indicate the cost
per QALY gained by adding a psychological intervention
to advocacy for women experiencing DVA. Costs and out-
comes will not be discounted, as the study will be limited
to a period of 12 mo. The effect of uncertainty in unit cost
estimates or assumptions about resource use will be
addressed in sensitivity analyses. Uncertainty in the cost-
effectiveness/utility ratios resulting from participant vari-
ation in resource use and effectiveness will be captured by
estimating confidence intervals around the net benefit
statistic and estimating cost-effectiveness acceptability
curves.
Qualitative analysis
The aims of the qualitative analysis will be twofold: first
to understand the meaning and perceived effectiveness
of the intervention in the context of the women’s lives,
and second to deepen our understanding of the process
of identity change for women as they move through
some or all of the stages from victim to survivor to
thriver [58]. The first analytic strand will provide im-
portant insights into contextual and motivational factors
for the women in relation to the intervention. This will
enable hypotheses to be tested about factors likely to act
as barriers or facilitators to the effectiveness of the inter-
vention, for example, practical arrangements for SPA
sessions, such as the availability of a safe location or
child care or finding suitable times to attend sessions, as
well as factors relating to women’s expectations or prior
experiences in help-seeking and their relationships with
provider organizations and individual SPA workers.
Comparisons will be made with the help-seeking experi-
ences of women in the control arm of the study. The
second analytic strand will be conducted using the per-
spective of interpretive phenomenological analysis which
explores the lived experience of participants [59]. This
approach allows for a deeper exploration and interpret-
ation of women’s experiences. Insights gained will enable
the research team to critique and add to the theoretical
development in the field of DVA, most of which has
been generated in the United States [60-63].
Discussion
This study is the first randomized controlled trial of an
intervention to improve the psychological well-being of
women experiencing DVA in a UK setting. The study is
a collaboration with third-sector agencies that already
provide a valuable service for this client group through
provision of specialist support and advocacy. If a psycho-
logical program delivered by DVA advocates improves
mental health outcomes for women who have experiencedDVA, and if this is a cost-effective intervention, the PATH
model will be appropriate for commissioning by the NHS.
Study organization
The University of Bristol is the sponsor for this trial. The
study is funded through the UK National Institute for
Health Research as part of the PROVIDE (Programme of
Research On Violence In Diverse domestic Environments)
Programme Grant for Applied Research. The Centre for
Academic Primary Care at the University of Bristol is
coordinating the study and monitoring and verifying the
data and will analyze the results. A trial steering commit-
tee consisting of an independent chair and two other inde-
pendent members, along with the lead investigator and
other study investigators, will oversee the conduct of
the trial. An independent Data Monitoring and Ethics
Committee chaired by Harriet MacMillan, a domestic
violence trialist, and comprising a statistician, trial meth-
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